Drugs / MK-4464
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05514444 | Sep 2022 → Sep 2025 | neoplasm | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-4464 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05514444 ↗ |
| Route | Intravenous | “MK-4464 administered as an IV infusion every three weeks according to allocation and dose escalation.” NCT05514444 ↗ |